MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
DEINOVE (Euronext Growth Paris: ALDEI) (Paris:ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that it has obtained, jointly with ESPCI Paris1, a €300k grant from the ANR2 for the co-development of an innovative system for the isolation, culture and screening of bacteria.
The Deinodrop partnership research project, involving DEINOVE and ESPCI Paris, was selected by the ANR as part of the call for collaborative research projects in the field of Healthcare technologies. This two-year project has been granted €300k in funding.
This project, which will support the AGIR program, aims to develop an innovative microfluidic sorting system, into drops containing environmental bacteria, in which each drop constitutes a microreactor. Once developed, this technology will offer many benefits to accelerate research and increase the success rate of the AGIR program:
- Increased screening sensitivity, for better detection of antibiotics of interest;
- Increased bacterial screening and sorting rate, up to 800 drops per second, while optimizing the amount of reagents used;
- Ability to detect, sort and analyze bacteria said to be non- cultivable under conventional laboratory conditions.
"We are proud that the DEINODROP project has been selected by the ANR. Only 15% of the projects submitted are selected, obtaning this funding rewards the quality of our technology " says Raphaël CALBRIX, Head of the DEINOVE Banking and Robotics platform. "Our objective is to develop a breakthrough technology in bacterial culture and selection in order to be able to analyze considerable quantities of microorganisms and discover new antibiotic activities that could address the major challenge of antibiotic resistance. »
ABOUT THE AGIR PROGRAM
The AGIR program – Antibiotics Against Resistant Infectious Germs – was selected in 2017 by the Investments for the Future Program and receives from Bpifrance a financial support of €14.6m over 5 years.
AGIR, a platform dedicated to the search for unprecedented antibiotic structures from rare bacterial strains
The AGIR program aims to explore a wide-ranging biodiversity, mainly rare micro-organisms in order to identify and develop a portfolio of drug candidates.
While the world lacks new antibiotics, research is still predominantly focused on a small number of micro-organisms of interest or on the construction by chemical synthesis of molecules derived from existing drugs.
Conversely, the AGIR program is developing new methods of collection, culture, evaluation of the antibiotic potential of rare bacterial strains, and optimization of the molecules of interest.
The AGIR program is run with the Charles Viollette Institute which brings its expertise in microbial and enzymatic engineering as well as identification of molecules.
An ambitious collaborative project strengthened by targeted strategic partnerships to broaden the scope of research
Capitalizing on its technology that allows it to automate and accelerate the analysis of large quantities of strains, DEINOVE aims to maximize the opportunities to discover new antibiotic structures by expanding its field of research beyond its own bacterial library.
The Company has entered into partnerships with several companies, including bioMérieux and Naicons, with portfolios of diverse strains collected as part of their pharmaceutical activities.
ABOUT DEINOVE
DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries.
DEINOVE has developed a unique and comprehensive expertise in the field of rare bacteria that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale. To do so, DEINOVE has been building and documenting since its creation an unparalleled biodiversity bank that it exploits thanks to a unique technological platform in Europe.
DEINOVE is organized around two areas of expertise:
- ANTIBIOTICS, New-generation anti-infective drugs: A first antibiotic candidate is now in Phase II. The Company is also pursuing the systematic exploration of biodiversity to supply its portfolio with new leads, drawing notably on partnerships with bioMérieux and Naicons (AGIR program supported by Bpifrance).
- BIOACTIVES, Active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: DEINOVE is already marketing a first cosmetic active ingredient, a second in partnership with Greentech and plans to launch new proprietary assets in 2020. Several other cosmetic actives are in development, including with Oléos (Hallstar Group) and Dow. It also runs a program in animal nutrition with Groupe Avril.
Within the Euromedecine science park located in Montpellier, DEINOVE employs 60 employees, mainly researchers, engineers, and technicians, and has filed more than 350 patent applications internationally. The Company has been listed on EURONEXT GROWTH® since April 2010.
Visit
www.deinove.com
1 ESPCI Paris: Paris Institute of industrial physics and chemistry
2 ANR: French National Research Agency
